22 February 2012 19:54 [Source: ICIS news]
NEW YORK (ICIS)--US chemical firm DuPont expects sales coming from its industrial biotechnology business to reach $1.2bn (€900m) in 2012, an increase of more than 50% from sales seen in 2011, a company executive said on Wednesday.
Industrial biotechnology accounted for 2% of DuPont’s $38bn global sales last year, said Jim Collins, president of DuPont’s industrial biotechnology business. Collins presented at the Jefferies Global Clean Technology Conference held in New York City.
The business is composed of 3 segments: bioactives, which include enzymes, proteins and peptides; biochemicals and biomaterials; and biorefineries, which include ethanol, biobutanol and bioprocessing aids.
In the renewable materials market, Collins cited continued opportunities for DuPont’s corn-based bio-propanediol (PDO), especially in the carpet applications sector, which occupies a large share of industrial biotechnology sales last year.
“Our partner, US carpet manufacturer Mohawk, has been able to take market share last year using our bio-PDO despite slowed housing market,” said Collins.
“We are building the same type of collaboration in other end markets such as in apparel and cosmetics,” Collins added.
About 135m lb/year (61m kg/year) of bio-PDO in Loudon, Tennessee, is currently produced under the DuPont Tate & Lyle partnership.
In biofuels, DuPont is expected to start construction of its 27.5m gal/year (104.1m litres/year) cellulosic ethanol biorefinery in Nevada, Iowa, this year. The ethanol plant is expected to start in late 2013.($1 = €0.75)
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections